KemPharm, Inc. (KMPH) Analysts See $-0.69 EPS

March 3, 2018 - By Darrin Black

 KemPharm, Inc. (KMPH) Analysts See $ 0.69 EPS

Analysts expect KemPharm, Inc. (NASDAQ:KMPH) to report $-0.69 EPS on March, 8.They anticipate $0.01 EPS change or 1.47 % from last quarter’s $-0.68 EPS. After having $-0.68 EPS previously, KemPharm, Inc.’s analysts see 1.47 % EPS growth. The stock increased 0.84% or $0.05 during the last trading session, reaching $6. About 248,035 shares traded or 77.16% up from the average. KemPharm, Inc. (NASDAQ:KMPH) has declined 32.16% since March 3, 2017 and is downtrending. It has underperformed by 48.86% the S&P500.

KemPharm, Inc. (NASDAQ:KMPH) Ratings Coverage

Among 5 analysts covering KemPharm (NASDAQ:KMPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. KemPharm had 18 analyst reports since August 14, 2015 according to SRatingsIntel. As per Sunday, February 25, the company rating was maintained by Oppenheimer. The firm has “Buy” rating given on Thursday, August 10 by Canaccord Genuity. The rating was maintained by Roth Capital with “Buy” on Friday, August 11. Canaccord Genuity maintained the shares of KMPH in report on Friday, February 23 with “Buy” rating. On Tuesday, December 20 the stock rating was reinitiated by Canaccord Genuity with “Buy”. The firm has “Buy” rating given on Thursday, September 17 by Canaccord Genuity. The firm earned “Buy” rating on Wednesday, June 28 by Oppenheimer. The firm has “Buy” rating given on Monday, September 11 by Canaccord Genuity. The stock of KemPharm, Inc. (NASDAQ:KMPH) earned “Buy” rating by Oppenheimer on Thursday, August 10. Oppenheimer maintained the shares of KMPH in report on Friday, September 18 with “Outperform” rating.

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. The company has market cap of $87.94 million. The Company’s lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. It currently has negative earnings. The firm is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders.

More news for KemPharm, Inc. (NASDAQ:KMPH) were recently published by: Globenewswire.com, which released: “KemPharm to Present at the RBC Capital Markets 2018 Global Healthcare Conference” on February 13, 2018. Reuters.com‘s article titled: “FDA approves KemPharm’s opioid painkiller” and published on February 23, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.